Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion is scheduled for June 4, 2026, at 2:35 p.m. EDT and will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website.
The company’s participation in this prominent healthcare investment conference underscores its progress in advancing proprietary NSAs designed to activate serotonin pathways believed to promote neuroplasticity. Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, aims to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, the company intends to improve the treatment landscape by introducing NSAs that aim to provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates, visit www.helus.com or follow the team on social media platforms.
The Jefferies Global Healthcare Conference is a key event for the healthcare investment community, and Helus Pharma’s inclusion highlights its potential in the mental health therapeutics space. Investors and stakeholders can access the full press release at https://ibn.fm/1QdP7. For the latest news and updates relating to HELP, visit the company’s newsroom at https://ibn.fm/HELP.
